136 citations
,
April 2013 in “Clinical Cancer Research” The study found that IPI-926 was well tolerated up to 160 mg once daily for 28-day cycles and showed activity as a single-agent treatment in Hedgehog pathway inhibitor-naïve patients with basal cell carcinoma.
127 citations
,
August 2016 in “The oncologist” This paper reviews adverse events related to hedgehog pathway inhibitors in advanced basal cell carcinoma patients, reporting no new clinical results but aiming to inform healthcare professionals for improved patient care.
72 citations
,
November 2017 in “Journal of developmental biology” This review discusses the role of Hedgehog signaling in epidermal and hair follicle development and its involvement in basal cell carcinoma, without reporting new empirical findings.
53 citations
,
May 2010 in “Journal of Cellular Physiology” This study found that mice lacking the Vitamin D receptor showed disrupted hair follicle cycling, which was partially restored with hedgehog signaling pathway activation, suggesting a role for this pathway in follicle regulation independent of vitamin D.
21 citations
,
November 2021 in “Cells” This review discusses the challenges and opportunities in targeting the hedgehog pathway for aggressive cancers, emphasizing the complexities of treatment resistance, immune response, and the potential of combining immune checkpoint inhibitors with hedgehog pathway inhibitors, but reports no new clinical results.